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Dynamic changes in the brain 
protein interaction network 
correlates with progression of Aβ42 
pathology in Drosophila
Harry M. Scholes1,7, Adam Cryar1,7, Fiona Kerr2,3,7, David Sutherland1, Lee A. Gethings4, 
Johannes P. C. Vissers4, Jonathan G. Lees1,6, Christine A. Orengo1*, Linda Partridge2,5* & 
Konstantinos Thalassinos1*
Alzheimer’s disease (AD), the most prevalent form of dementia, is a progressive and devastating 
neurodegenerative condition for which there are no effective treatments. Understanding the 
molecular pathology of AD during disease progression may identify new ways to reduce neuronal 
damage. Here, we present a longitudinal study tracking dynamic proteomic alterations in the brains 
of an inducible Drosophila melanogaster model of AD expressing the Arctic mutant Aβ42 gene. We 
identified 3093 proteins from flies that were induced to express Aβ42 and age-matched healthy 
controls using label-free quantitative ion-mobility data independent analysis mass spectrometry. 
Of these, 228 proteins were significantly altered by Aβ42 accumulation and were enriched for 
AD-associated processes. Network analyses further revealed that these proteins have distinct hub 
and bottleneck properties in the brain protein interaction network, suggesting that several may 
have significant effects on brain function. Our unbiased analysis provides useful insights into the 
key processes governing the progression of amyloid toxicity and forms a basis for further functional 
analyses in model organisms and translation to mammalian systems.
Alzheimer’s disease (AD) is a progressive and devastating neurodegenerative disease that is the most prevalent 
form of  dementia1. Symptoms initially present as episodic memory loss and subsequently develop into widespread 
cognitive impairment. Two brain lesions are pathological hallmarks of the disease: plaques and neurofibrillary 
tangles. Plaques are extracellular aggregates of amyloid beta (Aβ)2, whereas neurofibrillary tangles are intraneu-
ronal aggregates of hyperphosphorylated  tau3,4. In addition to these hallmarks, the AD brain experiences many 
other changes, including metabolic and oxidative  dysregulation5,6, DNA  damage7, cell cycle re-entry8, axon  loss9 
and, eventually, neuronal  death6,10.
Despite a substantial research effort, no cure for AD has been found. Effective treatments are desperately 
needed to cope with the projected increase in the number of new cases as a result of longer life expectancy and 
an ageing population. Sporadic onset is the most common form of AD (SAD), for which age is the major risk 
factor. Familial AD (FAD)—a less common (< 1%), but more aggressive, form of the disease—has an early onset 
of pathology before the age of  6511. FAD is caused by fully penetrant mutations in the Aβ precursor protein 
(APP) and two subunits—presenilin 1 and presenilin 2—of the Ɣ-secretase complex that processes APP in the 
amyloidogenic pathway to produce Aβ. Whilst the exact disease mechanisms of AD are not yet fully under-
stood, this has provided support for Aβ accumulation as a key player in its cause and  progression1. Aβ42—a 42 
amino acid variant of the peptide—is  neurotoxic12, necessary for plaque  deposition13 and sufficient for tangle 
 formation14. The Arctic mutation in Aβ42 (Glu22Gly)15 causes a particularly aggressive form of familial AD 
that is associated with an increased rate and volume of plaque  deposition16. Genetic analyses of SAD, however, 
suggest a complex molecular pathology, in which alterations in neuro-inflammation, cholesterol metabolism 
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and synaptic recycling pathways may also be required for Aβ42 to initiate the toxic cascade of events leading to 
tau pathology and neuronal damage in dementia.
Comparison of proteomic analyses of post-mortem human brains have further revealed an increase in meta-
bolic processes and reduction in synaptic function in  AD17. Oxidised proteins also accumulate at early stages 
in AD brain, probably as a result of mitochondrial ROS  production18, and redox proteomic approaches suggest 
that enzymes involved in glucose metabolism are oxidised in mild cognitive impairment and  AD19,20. Moreover, 
phospho-proteomic approaches have revealed alterations in phosphorylation of metabolic enzymes and kinases 
that regulate phosphorylation of chaperones such as HSP27 and crystallin alpha  B21. Of note, however, there is 
little proteomic overlap between studies using post-mortem human brain tissue, which may reflect the low sample 
numbers available for such studies, differences in comorbidities between patients and confounding post-mortem 
 procedures17. Although valuable, post-mortem studies also reflect the end-stage of disease and, therefore, do not 
facilitate measurement of dynamic alterations in proteins as AD progresses.
Animal models of AD, generated through transgenic over-expression of human APP or tau, provide an 
opportunity to track proteomic alterations at pre- and post-pathological stages, thus facilitating insight into 
the molecular mechanisms underlying disease development and revealing new targets for drugs to prevent AD 
progression. Analyses of transgenic mice models of AD have revealed some overlapping alterations in metabolic 
enzymes, kinases and chaperones with human AD  brain17. Only one study, however, has tracked alterations in 
protein carbonylation over time, showing increases in oxidation of metabolic enzymes (alpha-enolase, ATP 
synthase α-chain and pyruvate dehydrogenase E1) and regulatory molecules (14-3-3 and Pin1) in correlation 
with disease  progression22.
Adult-onset Drosophila models of AD have been generated by over-expressing human Aβ42 peptide exclu-
sively in adult fly neurons using inducible expression systems. These models have been shown to develop progres-
sive neurodegenerative phenotypes, such as reduced climbing ability, and shortened  lifespan23. Taking advantage 
of the short lifespan of the fly, and the flexible nature of the inducible model, we have performed a longitudinal 
study of the brain proteome to capture the effects of Aβ42-toxicity in the brain from the point of induction and 
across life. We identified 3093 proteins using label-free quantitative ion-mobility data independent analysis mass 
spectrometry (IM-DIA-MS)24, 1854 of which were common to healthy and Aβ42 flies. Of these, we identified 
228 proteins that were significantly altered in AD, some of which overlapped with normal ageing but the major-
ity of which were ageing-independent. Proteins altered in response to Aβ42 were enriched for AD processes 
and have statistically significant network properties in the brain protein interaction network. We also show that 
these proteins are likely to be bottlenecks for signalling in the network, suggesting that they comprise important 
proteins for normal brain function. Our data is a valuable resource to begin to understand the dynamic prop-
erties of Aβ42 proteo-toxicity during AD progression. Future functional studies will be required to determine 
the causal role of these proteins in mediating progression of AD using model organisms and to translate these 
findings to mammalian systems.
Results
Proteome analysis of healthy and Aβ42-expressing fly brains. Using an inducible transgenic fly 
line expressing human Arctic mutant Aβ42 (TgAD)23 (Fig. 1a), we confirmed a previously  observed23 reduction 
in lifespan following Aβ42 induction prior to proteomic analyses (Fig. 1b).
To understand how the brain proteome is affected as Aβ42 toxicity progresses, fly brains were dissected from 
healthy and Aβ42 flies at 5, 19, 31 and 46 days, and at 54 and 80 days for healthy controls, then analysed by label-
free quantitative IM-DIA-MS (Fig. 1c, Supplementary Data 1). 1854 proteins were identified in both healthy 
and Aβ42 fly brain from a total of 3093 proteins (Fig. 1d), which is typical for recent fly proteomics  studies25,26.
For the 1854 proteins identified in both healthy and Aβ42 flies, we assessed the reliability of our data. Pro-
teins were highly correlated between technical and biological repeats (Fig. S1). We used principal component 
analysis of the protein abundances to identify sources of variance (Fig. 1e). Healthy and Aβ42 samples are 
clearly separated in the first principal component, probably due to the effects of Aβ42. In the second principal 
component, samples are separated by increasing age, due to age-dependent or disease progression changes in 
the proteome. These results show that whilst ageing does contribute to changes in the brain proteome (8.7% 
of the total variance), much larger changes are due to expression of Aβ42 (70.6%) and this may reflect either a 
correlation with the ageing process or progression of AD pathology. We confirmed this result using hierarchical 
biclustering of protein abundances in Aβ42 versus healthy flies at 5 days (Fig. 1f). The results reveal that most 
proteins do not vary significantly in abundance with age in healthy flies, but many proteins are differentially 
abundant in Aβ42 flies.
Analysis of brain proteome dysregulation in Aβ42 flies. We next identified the proteins that were 
significantly altered following Aβ42 expression in the fly brain. To achieve this, we used five methods commonly 
used to analyse time course RNA-Seq  data27 and classified proteins as significantly altered if at least two methods 
detected  them28. We identified 228 significantly altered proteins from 740 proteins that were detected by one or 
more methods (Fig. 2a; Supplementary Data 2). A comparison of popular RNA-Seq analysis  tools29 showed that 
 edgeR30 has a high false positive rate and variable performance on different data sets, whereas,  DESeq231 and 
 limma32 have low false positive rates and perform more consistently. We observed a similar trend in our data 
set. limma and DESeq2 detected the lowest number of proteins, with 21 proteins in common (Fig. S2a). edgeR 
detected more proteins, of which 38 were also detected by DESeq2 and 16 by limma.  EDGE33 and  maSigPro34 
detected vastly more proteins, 464 of which were only detected by one method. Principal component analysis 
shows that edgeR, DESeq2 and limma detect similar proteins, whereas, EDGE and maSigPro detect very differ-
ent proteins (Fig. S2b).
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Figure 1.  Proteome analysis of healthy and AD fly brains. (a) Drosophila melanogaster transgenic model of 
AD (TgAD) that expresses Arctic mutant Aβ42 in a mifepristone-inducible GAL4/UAS expression system 
under the pan-neuronal elav promoter. (b) Survival curves for healthy and Aβ42 flies. Aβ42 flies were induced 
to express Aβ42 at 2 days. Markers indicate days that MS samples were collected. (c) Experimental design of 
the brain proteome analysis. Aβ42 flies were induced to express Aβ42 at 2 days. For each of the three biological 
repeats, 10 healthy and 10 Aβ42 flies were collected at 5, 19, 31 and 46 days, as well as 54 and 80 days for healthy 
flies. Proteins were extracted from dissected brains and digested with trypsin. The resulting peptides were 
separated by nanoscale liquid chromatography and analysed by label-free quantitative IM-DIA-MS. (d) Proteins 
identified by IM-DIA-MS. (e) Principal component analysis of the IM-DIA-MS data. Axes are annotated with 
the percentage of variance explained by each principal component. (f) Hierarchical biclustering using relative 
protein abundances normalised to their abundance in healthy flies at 5 days.
4
Vol:.(1234567890)
Scientific Reports |        (2020) 10:18517  | https://doi.org/10.1038/s41598-020-74748-9
www.nature.com/scientificreports/
Although these methods should be able to differentiate between proteins that are altered in Aβ42 flies from 
those that change during normal ageing, we confirmed this by analysing healthy flies separately. In total, 61 
proteins were identified as significantly altered with age (Fig. S3; Supplementary Data 3), of which 30 were 
also identified as significantly altered in AD (Fig. 2b) and 31 in normal ageing alone. These proteins are not 
significantly enriched for any pathways or functions. Based on our results, we concluded that the vast majority 
of proteins that are significantly altered in AD are not altered in normal ageing and that AD causes significant 
dysregulation of the brain proteome.
Of the 31 proteins specifically altered in ageing (Fig. S4), 10 decreased with age (Acp1, CG7203, mRPL12, 
qm, CG11017, HIP, HIP-R, PP02 and Rpn1), 15 increased with age (ade5, CG7352, RhoGAP68F, CG9112, PCB, 
Aldh, D2hgdh, CG7470, CG7920, RhoGDI, Aldh7A1, CG8036, Ssadh, muc and FKBP14) and four fluctuated 
throughout life (CG14095, His2A, RpL6 and SERCA).
To understand the dynamics of protein alterations following Aβ42 induction, we clustered the profiles of pro-
teins significantly altered in Aβ42 flies using a Gaussian mixture model (Fig. 2c). The proteins clustered best into 
four sets (Fig. S5), determined by the BIC, which was smallest with four clusters. In comparison to healthy flies, 
cluster 1 contains proteins that have consistently higher abundance in Aβ42 flies. Conversely, cluster 2 contains 
proteins that have lower abundance in Aβ42 flies. The abundances of proteins from clusters 1 and 2 are affected 
from the onset of disease at day 5, and remain at similar levels as the disease progresses. Proteins in cluster 3 
follow a similar trend in healthy and Aβ42 flies and increase in abundance with age. However, cluster 4 proteins 
decrease in abundance as the disease progresses, whilst remaining steady in healthy flies.
We performed a statistical Gene Ontology enrichment analysis on each cluster but found no enrichment of 
terms. Furthermore, we also saw no enrichment when we analysed all 228 proteins together.
Brain proteins significantly altered by Aβ42 have distinct network properties. Following the 
analyses of brain proteome dysregulation in Aβ42 flies, we analysed the 228 significantly altered proteins in the 
context of the brain protein interaction network to determine whether their network properties are significantly 
different to the other brain proteins. We used a subgraph of the  STRING35 network induced on the 3093 proteins 
identified by IM-DIA-MS (see Networks section in the Methods for more details). This subgraph contained 183 
of the 228 significantly altered proteins (Fig. S6; Supplementary Data 4). We then calculated four graph theoretic 
network properties (Fig. 3a) of these 183 significantly altered proteins contained in this network: degree, the 
number of edges that a node has; shortest path, the smallest node set that connect any two nodes; largest con-
nected component, the largest node set for which all nodes have at least one edge to any of the other nodes; and 
betweenness centrality, the proportion of all shortest paths in the network that a particular node lies on.
Figure 2.  Brain proteome dysregulation in AD. (a) Proteins significantly altered in AD were identified using 
five methods (EDGE, edgeR, DESeq2, limma and maSigPro) and classified as significantly altered if at least two 
methods detected them. (b) Significantly altered proteins in AD (from a) and ageing. (c) Significantly altered 
protein abundances were z score-transformed and clustered using a Gaussian mixture model.
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We performed hypothesis tests and found that these proteins have statistically significant network properties. 
Firstly, the significantly altered proteins make more interactions than expected (mean degree P < 0.05; Fig. 3b). 
Therefore, these proteins may further imbalance the proteome by disrupting the expression or activity of proteins 
they interact with. Secondly, not only are these proteins close to each other (mean shortest path P < 0.05; Fig. 3c), 
but also 129 of them form a connected component (size of largest connected component P < 0.01; Fig. 3d). These 
two pieces of evidence suggest that Aβ42 disrupts proteins at the centre of the proteome. Lastly, these proteins 
lie along shortest paths between many pairs of nodes (mean betweenness centrality P < 0.01; Fig. 3e) and may 
control how signals are transmitted in cells. Proteins with high betweenness centrality are also more likely to be 
essential genes for  viability36. Taken together, these findings suggest that the proteins significantly altered in AD 
are important in the protein interaction network.
Predicting the severity of Aβ42-induced protein alterations using network properties. We 
predicted how severely particular Aβ42-associated protein alterations may affect the brain using two network 
properties—the tendency of a node to be a hub or a bottleneck. In networks, nodes with high degree are hubs 
for communication, whereas nodes with high betweenness centrality are bottlenecks that regulate how signals 
propagate through the network. Protein expression tends to be highly correlated to that of its neighbours in the 
protein interaction network. One exception to this rule, however, are bottleneck proteins, whose expression 
tends to be poorly correlated with that of its  neighbours36. This suggests that the proteome is finely balanced and 
that the expression of bottleneck proteins is tightly regulated to maintain homeostasis. We analysed the hub and 
bottleneck properties of the significantly altered proteins and identified four hub-bottlenecks and five nonhub-
bottlenecks that correlate with Aβ42 expression (Fig. 4a) and analysed how their abundances change during 
normal ageing and as pathology progresses (Fig. 4b).
Non-hub bottleneck proteins (Fig. 4b) Acs1 and Got2 levels were stably expressed throughout normal age-
ing in our healthy flies but increased upon Aβ42 induction and continued to rise with age in Aβ42 flies. On the 
other hand, Echs1 abundance increased in healthy flies during normal ageing, but its levels were reduced upon 
Aβ42 induction and its ageing-dependent increase was diminished in Aβ42 flies compared to controls. Levels 
of mt:CoII (a COX subunit) declined with age in healthy control, but not in Aβ42, fly brain, although its expres-
sion was downregulated compared to controls at all time-points following Aβ42 induction. Finally, the cuticle 
protein Acp65Aa was also upregulated in Aβ42 flies compared to controls, but levels fell sharply between 5 and 
19 days of age.
Figure 3.  Significantly altered proteins have statistically significant network properties in the brain protein 
interaction network. (a) Network properties that were calculated: degree, the number of edges that a node has; 
shortest path, the smallest node set that connect any two nodes; largest connected component, the largest node set 
for which all nodes have at least one edge to any of the other nodes; and betweenness centrality, the proportion 
of all shortest paths in the network that a particular node lies on. Using a subgraph of the STRING network 
induced on the 3093 proteins identified by IM-DIA-MS in healthy and Aβ42 flies, the significance of four 
network characteristics were calculated for the 183 significantly altered proteins contained in this subgraph. (b) 
Mean degree; (c) mean shortest path length between a node and the remaining 182 nodes; (d) the size of the 
largest connected component in the subgraph induced on these nodes; and (e) mean betweenness centrality. 
One-sided non-parametric P values were calculated using null distributions of the test statistics, simulated by 
randomly sampling 183 nodes from the network 10,000 times.
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Of the four hub-bottlenecks (Fig. 4b) Hsp70A was significantly upregulated at early time-points (5 days) 
in Aβ42 flies, dropped between days 5 and 31 post-induction, then increased at later time-points, compared 
to healthy controls which exhibited stable expression of this protein throughout life. We found that Gp93 was 
increased across age in Aβ42 flies compared to controls, possibly suggesting an early and sustained protective 
mechanism against Aβ42-induced damage. DNA topoisomerase 2 (Top2), an essential enzyme for DNA double-
strand break repair, was decreased in Aβ42 flies, following a pattern which mirrors changes in its expression 
with normal ageing. Finally, we found that actin (Act57B) was increased in Aβ42 flies but declined with age, in 
comparison to control fly brains which displayed stable expression across life.
Due to the importance of these hub and bottleneck proteins in the protein interaction network, we predict 
that AD-associated alterations in their abundance will likely have a significant effect on the cellular dynamics 
of the brain.
Dysregulated genes are associated with known AD and ageing network modules. Finally, we 
clustered the protein interaction network into modules and performed a Gene Ontology enrichment analysis on 
modules that contained any of the 228 significantly altered proteins. We saw no Gene Ontology term enrichment 
when we tested these proteins clustered according to their abundance profiles (Fig. 2c), presumably because the 
proteins affected in AD are diverse and involved in many different biological processes. However, by testing 
network modules for functional enrichment, we exploited the principle that interacting proteins are function-
ally associated. Using a subgraph of the STRING network containing the significantly altered proteins and their 
directly-interacting neighbours (see Networks section in the Methods for more details), we used  MCODE37 
to find modules of densely interconnected nodes. We chose to include neighbouring proteins to compensate 
for proteins that may not have been detected in the MS experiments due to the stochastic nature of observing 
peptides and the wide dynamic range of biological  samples38. The resulting subgraph contained 4842 proteins, 
including 183 of the 228 significantly altered proteins, as well as 477 proteins that were only identified in healthy 
or Aβ42 flies and 3125 proteins that were not identified in our IM-DIA-MS experiments. 12 modules were 
present in the network (Fig. 5, Supplementary Data 5). Module sizes range from 302 to 17 nodes. The smallest 
module (MCODE module 8) is shown in Fig. S7. The proportion of these modules that were composed of signifi-
cantly altered proteins ranged from 0 to 8%. All but one of the modules were enriched for processes implicated in 
AD and ageing (Fig. 5, Supplementary Data 6), including respiration and oxidative phosphorylation, transcrip-
tion and translation, proteolysis, DNA replication and repair, and cell cycle regulation. ApoB was found in the 
second highest scoring module that contains proteins involved in translation and glucose transport55 (Fig. 5).
We analysed the 31 proteins significantly altered in normal ageing, but not AD (Supplementary Data 3). Of the 
29 proteins that were contained in the STRING network, 24 interact directly with at least one of the AD signifi-
cantly altered proteins, suggesting an interplay between ageing and AD at the pathway level. Using a subgraph of 
the STRING network induced on these proteins and their 1603 neighbours, we identified eight network modules 
(Supplementary Data 7) that were enriched for ageing  processes39, including respiration, unfolded protein and 
oxidative damage stress responses, cell cycle regulation, DNA damage repair, and apoptosis.
Figure 4.  Analysis of hubs and bottlenecks in the brain protein interaction network. In networks, nodes with 
high degree are hubs and nodes with high betweenness centrality are bottlenecks. (a) Degree (hub-ness) is 
plotted against betweenness centrality (bottleneck-ness) in the brain protein interaction network for all proteins 
identified by IM-DIA-MS (grey circles). Of the significantly altered proteins (red circles), hub-bottleneck 
(> 90th percentile (PC) for degree and betweenness centrality) and nonhub-bottleneck proteins (> 90th PC for 
betweenness centrality) are highlighted (filled red circles). (b) Profiles of significantly altered bottleneck proteins 
implicated in Aβ42 toxicity. Maximum abundances are scaled to 1. Numbers in parentheses denote which 
cluster from Fig. 2c the protein was in.
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Discussion
Despite the substantial research effort spent on finding drugs against AD, effective treatments remain elusive. 
There is a need to better understand the molecular processes that govern the onset and progression of the complex 
pathologies observed in this condition to help identify new drug targets to treat and prevent AD.
Analysis of post-mortem human brain tissue is an important way to study dementia, but cannot capture the 
progression of pathology from the initiation of disease. Due to their short lifespan and ease of genetic manipu-
lation, model organisms such as Drosophila melanogaster provide a tractable system in which to examine the 
progression of AD pathology across life. We performed a longitudinal study of the Drosophila brain proteome, 
using an inducible model of AD, label-free quantitative IM-DIA-MS and network analyses. We were able to track 
alterations in protein levels from the point of exposure to human Aβ42 and the widespread interaction of Aβ42 
with brain signalling networks as pathology progresses over the life course.
We identified 61 proteins that were significantly altered with age in fly brain, 31 of which were not altered in 
response to Aβ42. Of these, structural chitin proteins (Acp1 and CG7203), mitochondrial associated proteins 
(HemK1 and mRPL12), geranylgeranyl transferases (qm), and proteostasis proteins (HIP, HIP-R and Rpn1) were 
significantly downregulated with age. In agreement with these observations, loss of mitochondrial function and 
proteostasis are key features of the ageing  brain40. Recent studies also suggest a role for geranylgeranyl trans-
ferase I-mediated protein prenylation in mediating synaptogenesis and learning and  memory41,42. Our findings 
suggest that this may represent a novel mechanism of regulation and maintenance of these functions during 
ageing, which warrants further investigation. Proteins involved in inositol monophosphate (IMP) biosynthesis 
(ade5), endosome recycling (RhoGAP68F and RhoGDI), oxidation–reduction processes (D2hgdh, Aldh and 
Aldh7A1), pyruvate metabolism (PCB and muc), neurotransmitter function (Ssadh), and ER-related protein 
folding (FKBP14) were increased with age in our study. Oxidative damage is a key feature of ageing brain and 
loss of aldehyde dehydrogenase (Aldh) function, which detoxifies oxidative stress inducing aldehydes, has been 
shown to be associated with promoting age-related neurodegeneration and cognitive dysfunction in  mice43,44. 
Phosphatidylinositol signalling is important for stabilising mood and behaviour, and IMP inhibition is thought to 
partially mediate the beneficial effects of lithium in the treatment of bipolar  disorder45. Rho GTPases are involved 
in maintenance of synaptic  function41, and reductions in their levels correlate with ageing and increases in their 
expression with foraging behaviour in the brain of honey  bees46. Our finding that inhibitors of these enzymes 
(Rho GAPs and Rho GDIs) are upregulated in ageing fly brain further suggests that changes in their activity may 
mediate loss of synaptic function throughout life. Ageing is also characterised by a progressive loss of metabolic 
function, and studies suggest that ATP-generating metabolites, such as pyruvate, improve cognitive  function47 
as reflected by upregulation of pyruvate carboxylase and muc, a component of the pyruvate dehydrogenase 
complex, in our data set. Finally, several proteins fluctuated in expression across age in our flies, including those 
involved in DNA repair (His2A), protein translation (RpL6), and ER calcium homeostasis (SERCA), processes 
which have been previously reported in association with brain  ageing48–50. Although alterations in these proteins 
are independent of Aβ42 expression in our flies, further work is required to investigate their functional role in 
preserving brain function with age and their potential to increase the vulnerability of the ageing brain to neu-
rodegenerative diseases.
Our proteomic analyses identified Aβ42-induced alterations in levels of 228 proteins, which clustered into 
four groups. First, those which were either elevated (cluster 1) or reduced (cluster 2) in AD relative to controls 
throughout life, and dysregulation of which may initiate AD pathogenesis, may be involved in early stages of 
disease progression, or represent defense mechanisms that could be harnessed for protection. Second, those 
Figure 5.  Analysis of network modules enriched for AD or ageing processes. MCODE was used to identify 
network modules in a subgraph of the STRING network containing the significantly altered proteins and their 
directly-interacting neighbours. The size of the resulting 12 modules is plotted against the fraction of proteins 
in these modules that are significantly altered in AD. Module 2 is annotated as containing ApoB. Marker sizes 
denote the MCODE score for the module.
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which were altered in correlation with ageing in healthy and Aβ42 flies (cluster 3). Finally, those which changed 
in Aβ42 flies across life but independently of ageing-dependent effects in healthy controls (cluster 4). Further 
work is required to determine whether reduction of these proteins plays a causal role in disease pathogenesis that 
could be targeted therapeutically, or whether their decline represents a protective response to damage.
Moreover, computational analysis of these proteins revealed significant network properties within the fly brain 
proteome. Assessing hub and bottleneck properties, many of the Aβ42-induced proteomic changes represented 
alterations in bottleneck proteins suggesting that they play key roles in downstream cellular function. Of these, 
some display non-hub properties indicating that they are important for maintaining cellular homeostasis in a 
targeted fashion, whereas others also displayed hub properties suggesting that they are central in linking cellular 
signalling pathways to maintain cell function.
During the review of this manuscript, we were made aware of a study that compares the performance of 
different normalisation methods on quantitative label-free proteomics  data51. The authors of this study found 
that the variance stabilisation normalisation has the most desirable characteristics for normalising data from 
quantitative label-free proteomics. In this work, we used a quantile normalisation, however, we do not believe 
this method introduced any undesirable characteristics or biases.
We identified five nonhub-bottleneck proteins and four hub-bottleneck proteins, the expression of which was 
altered in Aβ42 flies relative to controls across life. Due to the importance of these hub and bottleneck proteins 
in the protein interaction network, we predict that AD-associated alterations in their abundance will likely have 
a significant effect on the cellular dynamics of the brain. Indeed, some of these proteins play key molecular roles 
in metabolism, protein homeostasis, protection against oxidative stress, and DNA damage, processes which have 
been shown to affect neuronal function and protect against proteo-toxicity. Acyl-CoA synthetase long chain 
(Acs1), Enoyl-CoA hydratase, short chain 1 (Echs1), and Aspartate aminotransferase (Got2), are metabolic 
enzymes with previous links to neuronal function and  damage6. Got2 produces the neurotransmitter L-glutamate 
from aspartate, is involved in assembly of synapses and becomes elevated following brain  injury52. Cytochrome c 
oxidase (COX), complex IV of the mitochondrial electron transport chain, uses energy from reducing molecu-
lar oxygen to water to generate a proton gradient across the inner mitochondrial membrane. Although Aβ is 
known to inhibit COX  activity53, the link between COX and AD is unclear. In AD patients, COX activity—but 
not abundance—is reduced, resulting in increased levels of  ROS54. However, in COX-deficient mouse models 
of AD, plaque deposition and oxidative damage are  reduced55. Hsp70A is a heat shock protein that responds to 
hypoxia and Gp93 is a stress response protein that binds unfolded proteins, consistent with responses to abnor-
mal Aβ42 aggregation in our flies. DNA topoisomerase 2 (Top2) is an essential enzyme for DNA double-strand 
break repair. Double-strand breaks occur naturally in the brain as a consequence of neuronal activity—an effect 
that is aggravated by Aβ7. As a consequence of deficient DNA repair machinery, deleterious genetic lesions 
may accumulate in the brain and exacerbate neuronal loss. The cuticle protein Acp65Aa is a chitin, this class of 
which have been detected in AD brains and suggested to facilitate Aβ  nucleation56. Finally, actin (Act57B) is a 
structural protein, and depolymerisation of F-actin filaments have been observed in a mouse AD model before 
onset of AD  pathology57. Alterations in these proteins may represent either adaptive responses to the presence 
of abnormal protein aggregates, such as Aβ42, or mediators of neuronal toxicity. Further functional genomic 
studies are therefore required to establish the causal role of these processes in governing onset and progression 
of AD pathology.
Assessing the human orthologs of these genes, identified using  DIOPT58, indicates that several of these bottle-
neck proteins have been previously implicated in association with AD or other neurological conditions in humans 
or mammalian models of disease. ACSL4 (Acs1 ortholog) has been shown to associate with synaptic growth 
cone development and mental  retardation59. Mutations in ECHS1 (Echs1 ortholog), an enzyme involved in mito-
chondrial fatty acid oxidation, associate with Leigh Syndrome, a severe developmental neurological  disorder60. 
Proteomic studies have revealed that GOT2 (Got2 ortholog) is down-regulated in infarct regions following 
 stroke61, and in AD patient  brain62. Integrating data from human post-mortem brain studies, HSPA1A (Hsp70Aa 
ortholog) upregulates in the protein interaction network of AD patients compared to healthy  controls63, and 
has recently been suggested to block APP processing and Aβ production in mouse  brain64. Synthetic, fibrillar, 
Aβ42 reduces expression of TOP2B (Top2 ortholog) in rat cerebellar granule cells and in a human mesenchymal 
cell line, suggesting this may contribute to DNA damage in response to  amyloid65. HSP90B1 (Gp93 ortholog) 
shows increased expression following TBI in  mice66, and associates with animal models of Huntington’s  disease67. 
Finally, ACTB (Act57B ortholog) has been implicated as a significant AD risk gene and central hub node using 
integrated network analyses across  GWAS68.
ACSL4, ECHS1, and HSP90B1 have no reported association with AD or related dementias, however, which 
suggests that our study has the potential to identify new targets in the molecular pathogenesis of this disease. 
Our study also provides additional information about the homeostasis of these proteins across life from the point 
of amyloid production. For example, the abundances of Acs1 and Got2 are elevated following Aβ42 induction 
and continue to increase with age relative to controls. Echs1 is reduced in Aβ42 flies compared to controls but 
increases across life in parallel with ageing-dependent increases in this protein. Structural proteins Acp65Aa 
and Act57B are elevated in response to Aβ42 but decline across life whilst remaining stable in control flies. Gp93 
and Top2 are either elevated or reduced in response to Aβ42 but mirror ageing-dependent alterations in their 
expression. mt:CoII is reduced following Aβ42 expression at all time-points, but reduced with ageing in controls. 
Hsp70A is increased early in Aβ42 flies, reduced to control levels in mid-life then elevated at late pathological 
stages whilst remaining stable in healthy controls.
Analysing Gene Ontology enrichment using network modules, to capture the diverse biological processes 
modified in AD, we identified 12 modules enriched for processes previously implicated in ageing and AD. This 
validates the use of our Drosophila model in identifying progressive molecular changes in response to Aβ42 that 
are likely to correlate with progression of cognitive decline in human disease. Further work is required to modify 
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the genes identified in our study at different ages, in order to elucidate whether they represent mediators of toxic-
ity as the disease progresses, factors which increase neuronal susceptibility to disease with age or compensatory 
protective mechanisms. Model organisms will be essential in unravelling these complex interactions. Our study 
therefore forms a basis for future analyses that may identify new targets for disease intervention that are specific 
to age and/or pathological stage of AD.
Materials and methods
Fly stocks. The TgAD fly line used in this  study23 contains the human transgene encoding the Arctic mutant 
Aβ42 peptide under the control of an Upstream Activation Sequence (UAS)69. Expression of Aβ42 was con-
trolled by  GeneSwitch70—a mifepristone-inducible GAL4/UAS expression system—under the pan-neuronal 
elav promoter. All flies were backcrossed for six generations into the  w1118 genetic background.
Flies were grown in 200 ml bottles on a 12 h/12 h light/dark cycle at constant temperature (25 °C) and humid-
ity. Growth media contained 15 g/l agar, 50 g/l sugar, 100 g/l autolysed yeast, 100 g/l nipagin and 3 ml/l propionic 
acid. Flies were maintained for two days after eclosion before females were transferred to vials at a density of 25 
flies per vial for the lifespan analysis and 10 flies per vial for the IM-DIA-MS analysis. Expression of Aβ42 was 
induced in TgAD flies by spiking the growth media with mifepristone to a final concentration of 200 µM. Flies 
were transferred to fresh media three times per week, at which point the number of surviving flies was recorded. 
For each of the three biological repeats, 10 healthy and 10 Aβ42 flies were collected at 5, 19, 31 and 46 days, as 
well as 54 and 80 days for healthy flies. Following anesthetisation with  CO2, brains were dissected in ice cold 
10 mM phosphate buffered saline snap frozen and stored at − 80 °C.
Extraction of brain proteins. Brain proteins were extracted by homogenisation on ice into 50 µl of 50 mM 
ammonium bicarbonate, 10 mM DTT and 0.25% RapiGest detergent. Proteins were solubilised and disulfide 
bonds were reduced by heating at 80 °C for 20 min. Free cysteine thiols were alkylated by adding 20 mM IAA 
and incubating at room temperature for 20 min in darkness. Protein concentration was determined and samples 
were diluted to a final concentration of 0.1% RapiGest using 50 mM ammonium bicarbonate. Proteins were 
digested with trypsin overnight at 37 °C at a 50:1 protein:trypsin ratio. Additional trypsin was added at a 100:1 
ratio the following morning and incubated for a further hour. Detergent was removed by incubating at 60 °C 
for 1 h in 0.1% formic acid. Insoluble debris was removed by centrifugation at 14,000×g for 30 min. Supernatant 
was collected, lyophilised and stored at − 80 °C. Prior to lyophilisation peptide concentration was estimated by 
nanodrop (Thermo Fisher Scientific, Waltham, MA).
Label-free quantitative IM-DIA-MS. Peptides were separated by nanoscale liquid chromatography (LC) 
by loading 300 ng of protein onto an analytical reversed phase column. IM-DIA-MS analysis was performed 
using a Synapt G2-Si mass spectrometer (Waters Corporation, Manchester, UK). The time-of-flight analyzer of 
the instrument was externally calibrated with a NaCsI mixture from m/z 50 to 1990. Spectra were acquired over 
a range of 50–2000 m/z. Each biological repeat was analysed at least twice to account for technical variation.
LC–MS data were peak detected and aligned by Progenesis QI for proteomics (Waters Corporation). The prin-
ciples of the embedded search algorithm for DIA data has been described  previously71. Proteins were identified 
by searching against the Drosophila melanogaster proteome in UniProt, appended with common contaminants, 
and reversed sequence entries to estimate protein identification false discovery rate (FDR) values, using previ-
ously specified search  criteria72. Peptide intensities were normalised to control for variation in protein loading 
and relative quantification. Abundances were estimated by Hi3-based  quantitation73.
Data analysis. Proteins that were identified in both healthy and Aβ42 flies were considered for further 
analysis. Missing data were replaced by the minimum abundance measured for any protein in the same  repeat38. 
The data were quantile  normalised74, so that different conditions and time points could be compared reliably. 
Quantile normalisation transforms the abundances so that each repeat has the same distribution.
For PCA analysis, the data were  log10-transformed and each protein was standardised to zero mean and unit 
variance. Hierarchical biclustering was performed using the Euclidean distance metric with the complete linkage 
method. Prior to clustering, proteins were normalised to their abundance in healthy flies at 5 days.
Proteins that were identified by IM-DIA-MS in either healthy or Aβ42 flies were assessed for overrepresenta-
tion of Gene Ontology terms using  GOrilla75, which uses ranked lists of target and background genes. Proteins 
were ranked in descending order by their mean abundance. The type I error rate was controlled by correcting 
for multiple testing using the Benjamini–Hochberg method at an FDR of 5%.
Clusters of proteins were assessed for overrepresentation of GO-Slim terms in the Biological Process ontol-
ogy using Panther (version 13.1) with a custom background of the 3093 proteins identified by IM-DIA-MS in 
healthy or AD flies.
Identification of significantly altered proteins. Significantly altered proteins were identified using 
five methods that are frequently used to identify differentially expressed genes in time course RNA-Seq data. 
 DESeq231,  EDGE33,  edgeR30,  limma32 and  maSigPro34 are all available in R through Bioconductor. Dispersions 
were estimated from the biological and technical repeats. Unless otherwise stated, default parameters were used 
for all methods under the null hypothesis that a protein does not change in abundance between healthy and AD 
conditions in normal ageing. The type I error rate was controlled by correcting for multiple testing using the 
Benjamini–Hochberg method at a FDR of 5%. A protein was classified as significantly altered if two or more 
methods identified it.
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DESeq2 models proteins with the negative binomial distribution and performs likelihood ratio tests. A time 
course experiment was selected in EDGE using the likelihood ratio test and a normal null distribution. edgeR 
uses the negative binomial distribution and performs quasi-likelihood tests. limma fits linear models to the 
proteins and performed empirical Bayes F-tests. maSigPro fits generalised linear models to the proteins and 
performs log-likelihood ratio tests.
Significantly altered proteins were clustered using a Gaussian mixture model. Protein abundances were log10-
transformed and z scores were calculated. Gaussian mixture models were implemented for 1–228 clusters. The 
best model was chosen using the Bayesian information criterion (BIC), which penalises complex models:
where ln(L) is the log-likelihood of the model, n is the number of significantly altered proteins and k is the 
number of clusters. The model with lowest BIC was chosen.
Networks. All network analysis was performed using the Drosophila melanogaster STRING network (ver-
sion 10)35. Low confidence interactions with a ‘combined score’ < 0.5 were removed in all network analyses.
Network properties of the significantly altered proteins were analysed in the brain protein interaction network. 
A subgraph of the STRING network was induced on the 3093 proteins identified by IM-DIA-MS in healthy or 
Aβ42 flies and the largest connected component was selected (2428 nodes and 44,561 edges). The subgraph 
contained 183 of the 228 significantly altered proteins (Fig. S6; Supplementary Data 4). For these proteins, four 
network properties were calculated as test statistics: mean node degree; mean unweighted shortest path length 
between a node and the remaining 182 nodes; the size of the largest connected component in the subgraph 
induced on these nodes; and mean betweenness centrality. Hypothesis testing was performed using the null 
hypothesis that there is no difference between the nodes in the subgraph. Assuming the null hypothesis is true, 
null distributions of each test statistic were simulated by randomly sampling 183 nodes from the network 10,000 
times. Using the null distributions, one-sided non-parametric P values were calculated as the probability of 
observing a test statistic as extreme as the test statistic for the significantly altered proteins.
A subgraph of the STRING network was induced on the proteins significantly altered in AD and their 
neighbours and the largest connected component was selected (4842 nodes and 182,474 edges). The subgraph 
contained 198 of the 228 significantly altered proteins and was assessed for enrichment of Gene Ontology 
terms. Densely connected subgraphs were identified using  MCODE37. Modules were selected with an MCODE 
score > 10. As STRING is a functional interaction network, clusters of nodes may correspond to proteins from 
the same complex, pathway or functional family. Clusters were assessed for overrepresentation of GO-Slim terms 
in the Biological Process ontology using  Panther76 (version 13.1) with a custom background of the 3093 proteins 
identified by IM-DIA-MS in healthy or Aβ42 flies. Fisher’s exact tests were performed and the type I error rate 
was controlled by correcting for multiple testing using the Benjamini–Hochberg method at a FDR of 5%.
Open source software. Data analysis was performed in Python 3.6 (Python Software Foundation, https ://
www.pytho n.org) using  SciPy77,  NumPy78,  Pandas79, scikit-learn80,  NetworkX81,  IPython82 and  Jupyter83. Figures 
were plotted using  Matplotlib84 and seaborn.
Data availability
Raw MS data have been deposited to PRIDE.
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